Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Parodontax is a specialized topical toothpaste formulation containing a high concentration of sodium bicarbonate (67% w/w) and sodium fluoride (0.221-0.31% w/w), developed by GSK Consumer Healthcare for the treatment and prevention of gingivitis. The product works through a dual mechanism: the high concentration of sodium bicarbonate enhances the physical disruption and removal of dental plaque biofilm during brushing, which directly reduces gingival inflammation and bleeding. Simultaneously, sodium fluoride provides anti-caries benefits by promoting the remineralization of tooth enamel and increasing its resistance to acid-producing oral bacteria. Multiple randomized controlled trials have demonstrated that twice-daily use of this high-bicarbonate formulation significantly improves clinical markers of gingival health, such as the Modified Gingival Index (MGI) and Bleeding Index (BI), compared to standard fluoride toothpastes in adults with mild-to-moderate gingivitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Parodontax (GSK).